Regulation of P-glycoprotein 1 and 2 gene expression and protein activity in two MCF-7/Dox cell line subclones. by Davies, R. et al.
Briftsh Journal of Cancer (1996) 73, 307-315
© 1996 Stockton Press All rights reserved 0007-0920/96 $12.00 M
Regulation ofP-glycoprotein I and 2 gene expression and protein activity in
two MCF-7/Dox cell line subclones
R Davies, J Budworth, J Riley, R Snowden, A Gescher and TW Gant
MRC Toxicology Unit, PO Box 138, Lancaster Road, Leicester LEI 9HN, UK.
Summary The MCF-7 doxorubicin-resistant cell line MCF-7/Dox has been used extensively for studies of the
multidrug resistance phenomenon. Using fluorescence-activated cell sorting (FACS), these cells were separated
into two populations on the basis of rhodamine 123 (R123) accumulation. We designated these as low P-
glycoprotein (LP-gp) and high P-gp (HP-gp) cells on the basis of their P-gp content. Using the reverse
transcriptase-polymersase chain reaction technique controlled by homologous internal standards, we analysed
levels of MDRJ and MDR2 mRNA in each cell type. LP-gp and HP-gp cells had MDRI mRNA levels of
2.17+0.17 and 6.65+2.29 amol ng-l total RNA respectively, compared with 0.00088+0.00005 amol ng-1 in
wild-type MCF-7 cells (MCF-7/WT). MCF-7/WT cells additionally contained 0.023+0.016 amol ng-' of
MDR2 mRNA, which was unchanged in LP-gp cells, but lower than in HP-gp cells, which contained
0.42+0.08amol ng- . Both LP-gp and HP-gp cells contained increased copies of the MDRI gene. However,
the degree of gene amplification did not correlate with the changes in MDRI mRNA levels, indicating further
regulatory levels of gene expression. The level ofP-gp detected by MRK16 correlated with R123 accumulation.
HP-gp cells expressed a 10-fold higher level of P-gpl than LP-gp cells. However, there was only a 3-fold
increase in MDRI mRNA level in HP-gp cells compared with LP-gp cells. These data suggest that some
regulation ofP-gpl expression also occurred at the post-translational level. Phosphorylation ofP-gp by protein
kinase C (PKC)-ax is necessary for its activity. Our analysis of PKC-a, 0 and E isozyme levels, and subcellular
distribution, shows a co-regulation of expression with P-gp, suggesting a necessary role for PKC in P-gp
regulation.
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Multidrug resistance (MDR) caused by overexpression of the
membrane ATPase pump P-glycoprotein (P-gp) can be
induced in cells in culture by exposure to cytotoxic agents
at progressively increasing concentrations (Riordan and Ling,
1979; Kartner et al., 1983a,b; Chan et al., 1988). In vitro
levels ofresistance to the inducing agent of greater than 1000-
fold compared with wild-type cells have been achieved (Beck
et al., 1979; Shen et al., 1986a). P-gps are coded for by the
MDR gene family, the number of members of which varies
between species. Humans possess two MDR genes, MDR]
and MDR2 (Chin et al., 1989; Ng et al., 1989). Of these, only
MDRJ codes for a P-gp (P-gp 1) that can confer a drug
resistance phenotype when transfected into drug-sensitive
cells (Ueda et al., 1987; Choi et al., 1991). Multidrug-resistant
cells, particularly those which display high levels of
resistance, often possess an increased copy number of the
MDR] gene (Batist et al., 1986; Fairchild et al., 1987;
Endicott and Ling, 1989; Van der Bliek and Borst, 1989).
However, in clinical samples resistance levels due to P-gp
expression appear to be lower than those induced in vitro,
and gene amplification has rarely been observed (Efferth and
Osieka, 1993). Additionally, cells selected in vitro for lower
levels of drug resistance do not show MDRJ gene
amplification (Shen et al., 1986b; Kohno et al., 1994).
One enzyme system that seems to be an important post-
translational regulator of P-gp activity via phosphorylation is
protein kinase C (PKC). The phosphorylation state and
activity ofP-gp can be augmented by PKC activators, such as
tumour-promoting phorbol esters (Chambers et al., 1990,
1992; Ma et al., 1991) and inhibited by agents such as
staurosporine (Chambers et al., 1990, 1992; Chaudhary and
Roninson, 1992; Bates et al., 1993). Of the PKC isozymes,
only PKC-a has to date been identified as important in the
post-translational regulation of P-gp activity (Yu et al., 1991;
Ahmad and Glazer, 1993; Ahmad et al., 1994). We analysed
PKC expression levels and subcellular distribution to evaluate
possible candidates that may have a role to play in
phosphorylation and regulation of P-gp.
Doxorubicin-resistant MCF-7 cells (MCF-7/Dox) have
been used frequently as a model for the study of MDR
resistance and its modulation. These cells were initially
derived by exposure of the MCF-7 breast carcinoma cell
line to increasing concentrations of doxorubicin (Batist et al.,
1986). MCF-7/Dox cells show a 192-fold increase in
resistance towards doxorubicin and cross-resistance to a
variety of other drugs such as actinomycin D and vinblastine
(Batist et al., 1986). The resistance phenotype is stable for 3
months when the cells are maintained in drug-free medium. It
is not clear how P-gp-mediated drug resistance in these cells
is regulated at the genetic level and which molecular events
are required to maintain it. The cells are characterised by a
number of biochemical changes when compared with their
wild-type counterparts, in particular elevated expression of P-
gp, amplification of the MDR gene (Cowan et al., 1986;
Fairchild et al., 1987), augmented expression of glutathione
S-transferase (Batist et al., 1986), and increased expression of
PKC (Fine et al., 1988).
During a study to validate P-gp activity using rhodamine-
123 (R123) accumulation and efflux we detected the presence
of two cell populations in our culture of MCF-7/Dox cells
with differing rates of R123 efflux. We sorted these cells into
two lines with different P-gp levels and used them to explore
mechanisms of MDRJ and 2 gene regulation and the
involvement of PKC isoenzymes in the regulation of P-gp
activity.
Materials and methods
Cell culture and maintenance
MCF-7/WT and MCF-7/Dox cells were gifts from J
Carmichael, City Hospital, Nottingham, and were originally
obtained from K Cowan, NIH, Bethesda, MD, USA. The
cells were maintained in phenol red-free RPMI-1640 (Gibco/
BRL) supplemented with 10% heat-inactivated fetal bovine
serum (FBS) and 50 Mug ml X gentamycin.
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Flow cytometric analysis of rhodamine (RJ23) accumulation
and retention
Cells (1 x 106) were allowed to attach to 55 mm Petri dishes
(Falcon) for 1.5 h in 3 ml of complete medium. Following
cell attachment the medium was replaced with 5 ml of serum-
free medium and cells were cultured for 10 or 20 min with
1.66 jiM R123, After this incubation period cells were washed
with phosphate-buffered saline (PBS) and either harvested or
treated with 5 ml of fresh medium and maintained in culture
for 1.5 h to allow for dye efflux to occur before cell harvest.
Cells were detached by treatment with trypsin-EDTA at 4°C,
washed and resuspended in 1 ml of ice-cold PBS, and
10 jug ml-' propidium iodide (PI) was added. Flow cyto-
metric analysis of the cells was carried out using a Becton
Dickinson FACScan flow cytometer with excitation wave-
length set at 488 nm. R123 fluorescence was collected after
passage through a 515-545 nm bandpass filter, and PI
fluorescence was collected after passing through a 546-
606 nm bandpass filter. Single and multiparameter measure-
ments of R123 forward angle, side angle scatter, R123 and PI
fluorescence were collected for 10 000 events. Fluorescence
data were collected on a four decade log scale and analysed
using Lysis 2 software. Only R123 fluorescence from viable
cells (i.e. PI-excluding cells) were evaluated.
The effects of P-gp inhibitors on R123 accumulation and
efflux were studied by co-incubating cells with R123 and
inhibitor (5 jiM) for 10 min. The efflux of R123 over a 1.5 h
period was determined by incubating the cells in R123-free
medium but containing the inhibitor (5 gM).
Simultaneous detection of R123 accumulation and
P-gp levels
Cells (1 x 106) were allowed to accumulate R123 for 20 min
as described above, then harvested, resuspended in 250 pl
PBS containing 10% normal goat serum (PBSG) and
incubated with 10 jug of MRK16 antibody (Kamiya
Biochemical Company, Thousand Oaks, CA, USA) at 4°C
for 30 min. After washing with ice-cold PBS the cells were
incubated with R-phycoerythrin (RPE)-conjugated F(ab')2
fragment of affinity-purified goat anti-mouse IgG (1: 10
dilution) (Dako) in PBSG for 30 min at 4°C, before being
washed with 2 ml of PBS and resuspended in 1 ml PBSG
before flow cytometric analysis. RPE fluorescence was
collected after passage through a 464-606 nm bandpass
filter. Duplicate analyses were performed in which the RPE-
conjugated antibody was replaced by PI (10 Mg ml-') so that
dead cells could be eliminated from the subsequent analysis.
Flow cytometric sorting of cells
Cells (4 x 107) were allowed to take up R123 for 20 min
before being harvested and resuspended in 4 ml of PBS at
4°C. The cells were sorted into high and low R123
accumulation populations using a FACS Vantage flow
cytometer. The cells were sorted at about 2000 per second
which resulted in an accumulation of 0.9 x 106 of both 'high'
and 'low' R123 fluorescing cells during a 40 min sorting
period. Only two populations were detectable by R123
accumulation in the MCF-7/Dox cell line. They were present
at a ratio of approximately 6:4 (low-high R123 fluores-
cence). Cells were sedimented by centrifugation and cultured.
After 2 h the culture medium was replaced.
Analysis of gene amplification
DNA was extracted from each of the cell lines by Iysis and
phenol-chloroform extraction. Three digests of the DNA
were made with EcoRI, HindIII and NcoI and 10 jig of each
digest electrophoresed on a 1% non-denaturing agarose gel.
After electrophoresis the DNA was transferred to Hybond N
(Amersham) by capillary transfer as previously described
(Sambrook et al., 1989). The DNA was cross-linked to the
nylon by UV light (Stratagene UV crosslinker, 120 000PJ)
and hybridised to probes pHDR5A (Ueda et al., 1987) and
MDR2pvuII (Currier et al., 1992), which detected MDRJ/2
and MDR2 gene fragments respectively. Hybridisation was
performed as previously described for the use of these probes
in Northern analysis for RNA expression (Gant et al., 1991,
1992). The blots were washed with 0.1 x SSC/0.1%SDS for
1 h at 42°C. Gels were visualised and quantitated using one
specific band for MDR] and MDR2 as described below for
quantitation of the RT-PCR gels.
Determination of cytotoxicity
Cells were seeded at 2 x 104 per 35-mm-diameter dish in 3 ml
of medium. After a 4 h incubation period to allow cell
attachment various concentrations of doxorubicin were
added. The toxicity of each concentration was determined
in duplicate dishes. The cells were left for 96 h (four
doubling times) and medium and doxorubicin was
replenished at 48 h. The cells were trypsinised and counted
using a Coulter Counter model ZM (Coulter Electronics,
Luton, UK). Growth inhibition was calculated as a
percentage of drug-free control. The concentration of
doxorubicin causing a 50% growth reduction (ICso) was
determined for each cell line.
RT-PCR analysis ofgene expression
RT-PCR was carried out using internal RNA standards.
The internal standard was a modified sequence of the cellular
RNA being amplified and which contained the same primer
sites. The modification made the internal standard sequence
slightly longer by duplication of a piece of sequence between
the primer sites. Details of primer construction are given
below. In the analysis between 20 and 300 ng of cellular
RNA was mixed with between 0.005 and 20 pg ofthe internal
standard RNA in a final reaction volume of 10 pl containing
20 mM Tris-HCl, pH 8.4, and 50 mM potassium chloride,
Mg2+ 2.5 mM, RNAsin (Promega) 1 U ul-', MMLV-reverse
transcriptase (Gibco/BRL) 10 U yl-', dNTP 1 mM, hexamers
(Pharmacia) approximately 15 pmol ,l-' and dithiothreitol
1 mM. Hexamers were annealed at 23°C for 10 min, products
extended at 420C for 45 min and the reaction terminated by
heating to 99°C before being quick chilled to 4°C (Futscher et
al., 1993). The PCR stage was carried out by the addition of
reagents (made as a master mix) to concentrations of
20 mMTris-HCl, pH 8.4, 50 mM potassium chloride, 2.5 mM
Mg2+, 1 pmol il-' sense and antisense primer (see below for
primers) of which 0.01 pmol pl-' sense primer was end
labelled with 33P, 0.05% w-I detergent (Gibcol/BRL) and
2.5 U Taq DNA polymerase in a final volume of 20 Ml. The
nucleotides were derived entirely from the original reverse
transcriptase reaction and so were at a final concentration of
0.5 mm for each nucleotide. PCR was carried out for 28
cycles at an annealing temperature of 550C for MDRI and
59°C for MDR2. Denaturation was at 95°C for 1 min in each
cycle except the first in which it was extended to 5 min. The
extension time was 2 min (72°C) in each cycle except the last
in which it was extended to 5 min. Annealing was for 2 min
in each cycle. For each set of reactions a negative control was
run that did not contain RNA. PCR products were not
detectable in this reaction.
After PCR a 5 Mil aliquot ofeach reaction was analysed on
an 8% non-denaturing gel. After drying, the gel was exposed
in a phosphorimager screen (Molecular Dynamics, Sunny-
vale, CA, USA). Expression of each RNA was analysed by
volume analysis with a local background using Image Quant
3.3 software (Molecular Dynamics).
To calculate absolute RNA concentrations five reactions
for each RNA sample were performed using the same
amount of cellular RNA in each, but an increasing amount
of the internal standard RNA. The ratio of the PCR band
volume from cellular RNA over band volume due to internal
standard RNA was plotted as a double loge plot against the
amount of the internal standard. The amount of internal
standard and cellular RNA are equal when the ratio of thesebands is 1 (log,= 0). Care was taken to ensure that the
experimental data spanned a ratio of 1 so that linearity to a
ratio ofone was not assumed. For each sample three analyses
were performed. Kinetics and reaction characteristics are
published in Zhang et al. (1996).
Construction of the MDR internal standard RNAs
The piece of the MDR] gene chosen for RT-PCR assay was
the region between bases 1991 (numbered from the adenosine
of the translation initiation codon) and 2416. The region was
amplified using primers 5'-AAAAAGATCAACTCGTAG-
GAGTG-3' (sense strand) and 5'-GCACAAAATACAC-
CAACAA-3' (antisense strand). The internal standard was
constructed by duplication of the region between base 2040
(HindlII site) and 2085 by PCR of this region using the sense
primer described above and an antisense primer spanning
bases 2065 to 2085 which had a HindIII site added at the 5'
end. Following PCR the product was cut with HindIII and
inserted into the HindIII site of the assay sequence. Thus the
internal standard was 51 bp longer than the assay region
allowing for inclusion of a second HindIII site. The whole
construct was contained in the pGem T vector (Promega) and
sequenced using a primer to the SP6 promoter region. The
plasmid was linearised using PstI before transcription of
sense RNA from the T7 promoter.
Construction of the MDR2 internal standard control was
very similar to that of MDR]. The area chosen for RT-PCR
assay spanned bases 1343 (numbered from the adenosine of
the translation initiation codon) and 1570. The region was
amplified using primers 5'-TGATGAGGGCACAATTAA-
CA-3' (sense) and 5'-GTGTCAAATTTCTGTGGAAT-3'
(antisense). The internal standard was made by duplication
ofthe sequence between bases 1408 and 1494 (NcoI site) using
the antisense primer above and a primer between bases 1408
and 1427 which had an NcoI site added to the 5' end. The PCR
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product was cut with Ncol and inserted into the analysis
region at the NcoI site. The whole construct was contained in
the pGEM4Z plasmid (Promega). The insert was sequenced
using a primer to the SP6 promoter and linearised using PstI
before transcription of sense RNA from the SP6 promoter.
Following transcription the size and integrity of the RNA
was checked on a denaturing agarose gel and concentration
assessed by determining optical absorbance at 260 nm. The
molecular weight of the construct was determined, taking
into account the additional sequence derived from the vector.
The RNA was aliquoted and stored at -80°C before use.
Western blot analysis of PKC isozymes
Cells were grown on 140 mm Petri dishes. When they
approached confluence cytosolic, particulate (membrane)
and nuclear fractions were prepared as previously described
(Greif et al., 1992) with some modifications (Stanwell et al.,
1994). The protein content of each sample was determined by
the method of Bradford, (1976).
Western blot analysis was performed as described
previously (Stanwell et al., 1994) loading 20 ,ug of protein
per lane. Monoclonal antibodies to PKC-a (TCS, Botolph
Claydon, UK) PKC-v and -0 (Afinitti, Nottingham, UK) and
a polyclonal antibody to PKC-C (Gibco, Paisley, UK) were
used. Detection was by enhanced chemiluminescence using an
ECL kit (Amersham, UK). Immunoreactivity was quantified
using a Molecular Dynamics computing densitometer and
Image Quant software.
Results
Identification of two subelones by R123 efflux
Accumulation and efflux of R123 was compared in MCF-7/
WT and MCF-7/Dox cells. Whereas MCF-7/WT cells
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Figure 1 R123 uptake and retention in MCF-7/WT (a-c) or MCF-7/Dox cells (d-f), and effect of verapamil (g, h). Cells were
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evident, both with a higher R123 efflux rate than that
observed in the parent MCF-7/WT cells. The cells in the two
populations were present at an approximately 6:4 (low-high
R123 fluorescence) ratio, and together constituted the entire
MCF-7/Dox population. When verapamil was present more
R123 was accumulated and R123 efflux was substantially
reduced. A similar result was obtained with reserpine, except
that this inhibitor was more potent than verapamil (data not
shown).
101 102 103 104
R123 fluorescence
Figure 2 R123 accumulation after exposure for 0min to the dye
of MCF-7/Dox cells (hatched area) or in the sorted 'low' (a) or
'high' (b) R123 fluorescence cells.
accumulated and retained R123 efficiently accumulation was
drastically reduced and efflux enhanced in MCF-7/Dox cells
(Figure 1). In our MCF-7/Dox cells two populations were
Cell sorting and culture on the basis of R123 effiux
The cells were sorted on the basis of their ability to efflux
R123, and established in culture. After sorting two cell
populations were obtained each of which was homogeneous
for R123 accumulation and efflux (Figure 2). To ensure that
the two separated cell lines were from the same source their
DNA was profiled and fingerprinted. The results of the
analysis (not shown) show that the low and high fluorescence
cells were indistinguishable on the basis of their DNA.
Analysis of P-gp levels using antibodies and FACS analysis
With the MRK-16 antibody (Figure 3) two cell populations
were evident, confirming that the MCF-7/Dox cell line is
composed of two populations with differing P-gp levels.
Correlation of P-gp content in MCF-7/Dox cells, detected by
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Figure 3 P-gp content in MCF-7/Dox (a and b), LP-gp (c) and HP-gp cells (d). Cells were stained with MRK-16 after incubation
with R123. Cross-hatched peaks show fluorescence in the absence, striped peaks in the presence of antibody. Cell incubations,
immunodetection and flow cytometry were carried out as described under Materials and methods.
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MRK-16 antibody, with their R123 accumulation showed
that the low R123 fluorescence cells had the higher P-gp
content. Likewise, the high R123 fluorescence cells expressed
the lower P-gp level. Thus, R123 accumulation was inversely
correlated with P-gp content (Figure 3). Furthermore, the
sorted high R123 fluorescence cell line expressed the lower P-
gp levels (Figure 3) and will therefore be referred to in the
following text as LP-gp (low P-gp) cells. The sorted R123 low
fluorescence cells expressed higher P-gp levels and will
therefore be referred to as HP-gp (high P-gp) cells. Both
for MRK-16 binding and R123 accumulation there was a 10-
fold difference between LP-gp and HP-gp cells.
Sensitiiitv of cells to dloxo-vouhicini cytotoxiciti'
Sensitivity of the cells against doxorubicin as reflected by ICso
values decreased in the order MCF-7/WT>LP-gp>MCF-7/
Dox>HP-gp (Table I).
the MCF-7/WT cells respectively. For MDR2 we found
similar amplification values of 8-, 36- and 65-fold respec-
tively.
AnalvCsi.s of cellular mnRNA level[s
Using RT-PCR with primers specific for the MDRI and
MDR2 genes and RNA internal standard controls it was
possible to detect and quantitate MDR] and MDR2 mRNA
in all four MCF-7 cell types. In the MCF-7/WT cells the
MDR] mRNA level was low at 0.00088+0.00005 amol ng-'
RNA compared with the MDR2 mRNA level, which was
0.023+0.016 amol ng-' RNA (Figure 5). MDR2 gene
expression occurs in many normal tissues (Brown et al.,
1993; Lee et al., 1993). Therefore it was not surprising that
MDR2 expression was higher than that of MDR] in the
Genie acnplification
MDR gene amplification was analysed in all four MCF-7 cell
types (Figure 4). In LP-gp, MCF-7/Dox and HP-gp cells, we
found MDRI gene amplifications of 9-, 40- and 78-fold over
Table I Doxorubicin cytotoxicity in MCF-7 Dox cell subclones
MCF-7 cell clon1e IC,0f' 0tllf
MCF7-WT 0.04 +0.01
LP-gp 0.61 +0.13
MCF-7 Dox 1.55 +0.05
HP-gp 1.99+0.12
a Cells (2 x 104) were exposed to various doxorubicin concentrations
for 96 h with the medium being replenished at 48 h. After 96 h the cells
were detached by trypsinisation and counted using a Coulter counter.
Inhibition of growth was calculated as a percentage of drug free
control.
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Figure 4 Amplification of the MDR] (_) and MDR2
genes in MCF-7 Dox, LP-gp and HP-gp cells over MCF-7TWT
cells. Using the pHDR5A probe. which detects the MDR] and
MDR2 genes, or the MDR2p,ulI probe, which detects only
MDR2, copy numbers of the MDRJ and 2 genes in each cell type
were determined as described under Materials and methods. The
results were quantitated using volume analysis on a phosphor-
imager. Equal DNA loading was assessed by hybridisation to a
probe for the GAPDH gene which spanned bases 2 to 1023 of the
GAPDH cDNA (Fort ct al., 1985).
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Figure 5 mRNA levels of MDR] (a) and MDR2 (b) in MCF-7,
WT (= ) LP-gp (I), MCF-7 'Dox (_), and HP-gp (E)
cells. Levels of mRNA for MDR] and MDR2 were determined
using internally controlled RT-PCR, as described in Materials
and methods. Results are the means + s.d. of three determinations,
except for MDR1 in MCF-7 WT cells, which is the mean of two
determinations.
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MCF-7/WT cells. In LP-gp cells MDRJ mRNA levels were
2.17+0.17 amol ng-' RNA, which constitutes a 2500-fold
increase over the MCF-7/WT cells. HP-gp cells contained
6.65+2.29 amol ng-1 RNA of MDRJ mRNA, a 7556-fold
increase. In HP-gp cells MDR2 mRNA levels were 0.42+0.08
amol ng-1 RNA, 18 times the level observed in MCF-7/WT
and LP-gp cells. MCF-7/Dox cells expressed levels of MDRJ
and MDR2 mRNA that were intermediate between the levels
of LP-gp and HP-gp cells, consistent with the ratio of LP-gp
and HP-gp subpopulations in the parent MCF-7/Dox cell
line.
a
C M N C M N C
Analysis of PKC isozymes
As PKC-xc has been shown to play a role in the regulation of
P-gp activity (Yu et al., 1991; Ahmad and Glazer, 1993;
Ahmad et al., 1994) levels and subcellular distribution of
PKC isozymes were examined. All three MCF-7 doxorubicin-
resistant cell lines expressed PKC-a, -C, -e and -6 (Figure 6
and Table II). Other PKC isozymes could not be detected by
Western blot analysis. Total PKC expression was similar
between LP-gp and HP-gp cells, but the isozyme distribution
pattern in these cells differed substantially from that seen in
M N
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MCF-7NWT LP-gp HP-gp MCF-7/WT LP-gp HP-gp
Figure 6 Western blot analysis (a) and distribution (b) of PKC isozymes in MCF-7/WT, LP-gp and HP-gp cells. Distribution is
expressed as a percentage of total cellular expression for each individual cell type. Expression was determined by Western blot
analysis with the appropriate antibodies in the cytosolic (_), membrane (kZ) and nuclear fractions (). Data for the MCF-7/
Dox cells were very similar to those in LP-gp/HP-gp cells, and are not shown. Values are the means+s.d. of three experiments,
statistical significance was determined (*P 0.05, **P<0.001) by analysis of variance.
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I 1% A %.- W. -- %Table II PKC expression in MCF-7/WT cells and their drug-
resistant counterparts
PKC MCF-7/Wr' MCF-7/Dox LP-gp HP-gp
aX +b + + ++ + ++++ +++±
0 +++ +++ +++
E ++++ + + +
.4 ~++++ ++ ++ ++
a Cells were harvested at near confluence and subcellular fractions
were isolated. Analysis of protein levels in the cytosolic, membrane
and nuclear fractions was by Western blotting with specific antibodies
as described in Materials and methods. Antibody binding was detected
using enhanced chemiluminescence and quantitated using a Molecular
Dynamics densitometer. bArbitrary measure based on consistent
observations from three separate experiments. A representative blot
is shown in Figure 6.
MCF-7/WT cells (Figure 6). Expression of PKC-a was
undetectable in MCF-7/WT cells but it was found at
identical levels in LP-gp and HP-gp cells. Most of the
enzyme was localised in the cytosol, whereas 1% was
associated with each of the membrane and nuclear
compartments. Overall expression of PKC-e and PKC-C in
both LP-gp and HP-gp cells was decreased compared with
MCF-7/WT cells (Table II). This decrease was mainly
accounted for by a loss of cytosolic enzyme. However, in
LP-gp and HP-gp cells PKC-a was located to a greater extent
in the nuclear and membrane fractions compared with MCF-
7/WT cells. PKC-0 was not detectable in MCF-7/WT cells,
but abundant in the resistant cells. In this case isozyme
distribution was relatively homogeneous between the sub-
cellular fractions.
Discussion
The multidrug-resistant MCF-7/Dox cell line was originally
derived in 1986 and has been widely used for studies of P-gp
(Batist et al., 1986). The results presented above show that
our MCF-7/Dox cells comprised two subclones that were
separable according to their ability to efflux R123. The
presence of two clones in the MCF-7/Dox cells has been
shown previously by MRK-16 antibody binding, but was not
discussed (Yu et al., 1991). In contrast another very recent
analysis with MRK16 found only one cell clone (Molinari et
al., 1994).
In the work outlined above we present six separate pieces
of evidence that suggest differences in P-gp expression levels
between LP-gp and HP-gp cells that constitute the MCF-7/
Dox cell line: (i) they accumulate and retain R123 differently;
(ii) they demonstrate different levels of immunoreactivity with
the anti-P-gpl antibody MRK-16; (iii) they exhibit different
degrees of MDRJ and MDR2 gene amplification; (iv) they
display different sensitivity towards doxorubicin; (v) they
possess different levels of MDRI and MDR2 mRNA; and (vi)
they are differentially susceptible towards verapamil.
MDRI mRNA levels were 2500- and 7556-fold greater in
the LP-gp and HP-gp cells respectively, than in MCF-7/WT
cells. The difference in MDR] mRNA levels between LP-gp
and HP-gp cells was therefore only 3-fold. However, both
R123 accumulation and MRK16 binding indicate a difference
of approximately one order ofmagnitude in the amount of P-
gpl protein between LP-gp and HP-gp cells. Therefore a
post-translational regulatory step for P-gpl stability may be
operative in HP-gp cells. Both MDR] and 2 genes were
amplified in LP-gp cells about 9- and 8-fold respectively, over
MCF-7/WT cells. In LP-gp cells this amplification translated
into an increase of MDRJ mRNA level of 2500, whereas
MDR2 mRNA was not increased. This discrepancy indicates
that a regulatory step was involved in the control of the
MDRI gene in which the rate of gene transcription or
mRNA half-life was increased about 250-fold over MCF-7/
WT cells to result in the observed mRNA level. The result
with MDR2 is more difficult to analyse, given the possibility
that the gene may not have been amplified intact. In the case
of HP-gp cells the picture was similar. MDRJ and MDR2
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gene amplification in HP-gp cells was 78- and 65-fold
respectively, over MCF-7/WT cells. However, MDR] and
MDR2 mRNA levels were increased 7556- and 18-fold
respectively. In analogy to LP-gp cells this difference
indicates an increase in MDRI gene transcription rate or
mRNA half-life of about 100-fold over MCF-7/WT cells. An
increase in MDRI transcription rate has been previously
observed in MCF-7/Dox, doxorubicin-resistant ovarian 2780
and human colon carcinoma SW620 cells (Morrow et al.,
1992; Madden et al., 1993). These data suggest that
regulation of mRNA level in the LP-gp and HP-gp cells
may occur to a greater degree at the transcriptional rather
than post-transcriptional level.
Correlation of the results obtained by fluorescence analysis
using the MRK-16 antibody with those observed for R123
accumulation suggests that R123 efflux was mediated
completely via P-gp. Furthermore, as MRK-16 is specific
for the P-gpl isoform (Schinkel et al., 1991, 1993), we
conclude that R123 efflux is driven by P-gpl and not P-gp2,
the mRNA for which was increased in HP-gp but not LP-gp
cells. This result is consistent with that previously obtained
by Ludescher et al. (1993) in B-cell chronic lymphocytic
leukaemia. All MCF-7-derived cell clones had detectable
MDR2 mRNA levels. The correlation between R123
accumulation and P-gpl levels as detected by MRK 16 in
LP-gp and HP-gp cells indicates that there is no additional
post-translational regulation of P-gp protein activity in HP-
gp in comparison with LP-gp cells.
As cPKC-a has been shown to play an important role in
the post-translational regulation of P-gp activity (Yu et al.,
1991; Ahmad and Glazer, 1993; Ahmad et al., 1994), we
analysed the level and distribution of PKC isozymes. In LP-
gp and HP-gp cells overall levels of PKC isozymes -o, -e, -C
and -0, were similar. However, compared with MCF-7/WT
cells the resistant cells expressed higher levels of cPKC-a and
nPKC-0 and lower levels of nPKC-e and aPKC-C. The
subcellular distribution of nPKC-e differed significantly
between LP-gp, HP-gp and MCF-7/WT cells. The resistant
cells possessed more nPKC-s in the membrane, and especially
the nucleus, than wild-type cells. The fact that this
distribution pattern locates nPKC-s more efficiently in close
vicinity to P-gp is commensurate with a role for this enzyme
in the post-translational regulation of P-gpl activity. This
finding is consistent with the report of Slapak et al., 1993,
who observed a decrease in overall PKC activity in the
cytosol of HL-60 cells with acquired vinblastine resistance
and an increase in enzyme content in the membrane fractions
compared with HL-60 WT cells. The results presented above
show for the first time that PKC-0 is present in MCF-7/Dox
cells and its subclones. Its absence in MCF-7/WT cells and
expression in all three cell compartments, particularly in the
membrane and nuclear fractions of LP-gp and HP-gp cells,
render it another candidate for post-translational regulation
of P-gp activity.
In conclusion we derived two cell lines from the widely
used MCF-7/Dox cell line, of the same origin, which differed
in their expression of both MDRI and MDR2 genes. This
difference translated into an altered level of P-gpl expressed
in the plasma membrane and a corresponding difference in
the ability of each cell line to efflux R123. In both LP-gp
and HP-gp cells the change in MDR2 mRNA over MCF-7/
WT cells was smaller than the increase in MDR2 gene copy
number indicating a decreased transcription rate or mRNA
stability or defective amplicon. The opposite was the case
for the MDR] gene in which the increase in MDR] mRNA
level was greater than that which could be accounted for by
increased gene copy number. This result indicates an
increased rate of MDR] gene transcription or mRNA
stability. Comparison of MRK-16 binding with R123
retention in each cell type is consistent with the hypothesis
that R123 efflux occurs only through P-gpl. Comparison of
P-gp protein level and mRNA levels between LP-gp and
HP-gp cells suggested that in addition to the transcriptional/
post transcriptional regulation of MDR] expression some
post-translational increase in protein stability occurred.Biochemical regulation of P-glycoprotein-mediated drug resistance
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However, the identical 10-fold difference in R123 accumula-
tion and P-gp levels between LP-gp and HP-gp cells
indicated no change in post-translational regulation of
protein activity. Analysis of PKC isozymes indicated a
dramatic increase in nPKC-ax and nPKC-0 levels in both LP-
gp and HP-gp cells over MCF-7/WT cells. In comparison
with MCF-7/WT cells nPKC-e expression was reduced
overall in the resistant cell types, however the enzyme was
distributed differently. More nPKC-s was located in the
membrane and nucleus, which might indicate an important
role for nPKC-s in the regulation of P-gpl activity.
Overall, the results highlight the complicated and multi-
faceted nature of regulation of the multidrug resistance
phenotype in MCF-7/Dox cells. A better appreciation of how
it is controlled will help to devise more efficacious therapies
to overcome P-gp-mediated drug resistance.
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